Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

SRPT | Sarepta Therapeutics Inc

Index	-	P/E	-	EPS (ttm)	-10.31	Insider Own	5.69%	Shs Outstand	93.28M	Perf Week	-2.80%
Market Cap	10.70B	Forward P/E	44.79	EPS next Y	2.56	Insider Trans	1.02%	Shs Float	87.97M	Perf Month	-1.09%
Income	-907.68M	PEG	-	EPS next Q	-1.26	Inst Own	86.89%	Short Float / Ratio	5.24% / 4.51	Perf Quarter	5.97%
Sales	1.00B	P/S	10.67	EPS this Y	-2.35%	Inst Trans	6.46%	Short Interest	4.61M	Perf Half Y	-10.62%
Book/sh	7.95	P/B	14.43	EPS next Y	-	ROA	-29.65%	Target Price	117.11	Perf Year	4.18%
Cash/sh	19.95	P/C	5.75	EPS next 5Y	41.76%	ROE	-123.67%	52W Range	100.15 - 159.89	Perf YTD	-11.45%
Dividend	-	P/FCF	-	EPS past 5Y	-56.35%	ROI	-43.10%	52W High	-28.24%	Beta	0.93
Dividend %	-	Quick Ratio	4.50	Sales past 5Y	45.19%	Gross Margin	81.74%	52W Low	14.57%	ATR	3.05
Employees	1162	Current Ratio	4.96	Sales Q/Q	11.89%	Oper. Margin	-50.80%	RSI (14)	43.39	Volatility	3.14% 2.32%
Optionable	Yes	Debt/Eq	1.84	EPS Q/Q	89.80%	Profit Margin	-90.46%	Rel Volume	1.68	Prev Close	119.93
Shortable	Yes	LT Debt/Eq	1.84	Earnings	Aug 02 AMC	Payout	-	Avg Volume	1.02M	Price	114.74
Recom	1.50	SMA20	-4.23%	SMA50	1.73%	SMA200	-7.47%	Volume	1,712,902	Change	-4.33%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-23-23	Downgrade	Evercore ISI	Outperform → In-line	$139
Apr-26-23	Initiated	SMBC Nikko	Outperform	$185
Apr-04-23	Initiated	Citigroup	Buy	$179
Mar-01-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$141 → $187
Dec-22-22	Reiterated	BTIG Research	Buy	$125 → $160
Dec-16-22	Upgrade	UBS	Neutral → Buy	$100 → $158
Apr-04-22	Resumed	Cantor Fitzgerald	Overweight	$140
Jan-05-22	Reiterated	Needham	Buy	$157 → $150
Dec-09-21	Upgrade	Oppenheimer	Perform → Outperform	$125
Nov-05-21	Upgrade	JP Morgan	Neutral → Overweight	$130
Sep-15-21	Upgrade	Guggenheim	Neutral → Buy
Aug-05-21	Upgrade	JP Morgan	Underweight → Neutral	$92 → $87
Jun-15-21	Initiated	BTIG Research	Buy	$110
Apr-26-21	Resumed	Credit Suisse	Neutral	$72
Jan-12-21	Downgrade	Citigroup	Buy → Neutral	$215 → $108
Jan-11-21	Downgrade	UBS	Buy → Neutral
Jan-08-21	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-08-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$95
Jan-08-21	Downgrade	JP Morgan	Overweight → Underweight	$96
Nov-11-20	Initiated	Berenberg	Hold

Show Previous Ratings

Sep-15-23 12:50PM	Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? (Investor's Business Daily)
08:37AM	Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks (Investor's Business Daily)
Sep-14-23 10:07AM	2 Top Growth Stocks to Buy With $500 (Motley Fool)
Sep-07-23 09:00AM	Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year (Business Wire)
Sep-05-23 08:30AM	Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
11:31AM	Loading…
Sep-01-23 11:31AM	Sarepta Therapeutics (SRPT) Up 12.7% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-31-23 06:15PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-30-23 11:09AM	FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23% (Zacks)
08:40AM	Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test (PR Newswire)
Aug-27-23 07:20PM	Insiders Pour Millions Into These 2 Stocks, Analysts Say They Have up to 120% Upside Heres Why You Should Pay Attention (TipRanks)
Aug-23-23 01:00PM	Is Sarepta Therapeutics Stock a Top Growth Vehicle? (Motley Fool)
Aug-22-23 10:00AM	3 Revolutionary Stocks I'd Buy Right Now Without Hesitation (Motley Fool)
Aug-13-23 08:08AM	Sarepta Therapeutics' Michael Chambers Acquires 19% More Stock (Simply Wall St.)
Aug-04-23 03:22PM	FDA-approved gene therapy invented at Nationwide Children's carries a $3.2M price tag. Here's why. (American City Business Journals)
Aug-03-23 11:28AM	Sarepta (SRPT) Q2 Loss Narrower Than Expected, Sales Miss (Zacks)
09:00PM	Loading…
Aug-02-23 09:00PM	Sarepta Therapeutics (SRPT) Q2 2023 Earnings Call Transcript (Motley Fool)
06:15PM	Sarepta Therapeutics (SRPT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
05:08PM	Sarepta Therapeutics: Q2 Earnings Snapshot (AP Finance)
04:05PM	Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments (Business Wire)
Jul-31-23 06:08PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-29-23 11:39AM	10 Oversold Biotech Stocks to Buy (Insider Monkey)
Jul-27-23 07:30AM	2 Biotech Growth Stocks I'd Buy Right Now (Motley Fool)
Jul-26-23 10:02AM	Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:30AM	Sarepta Therapeutics to Announce Second Quarter 2023 Financial Results (Business Wire)
Jul-25-23 10:01AM	Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-16-23 08:20AM	Sarepta Therapeutics Insider Ups Holding By 47% During Year (Simply Wall St.)
Jul-12-23 05:33PM	3 Biotech Stocks to Sell Before They Damage Your Portfolio (InvestorPlace)
Jul-05-23 08:30AM	Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million (Business Wire)
Jul-03-23 08:30AM	Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit (Business Wire)
Jun-30-23 06:20PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:45AM	Loading…
08:45AM	Sarepta Therapeutics' Stock Is Down 14% in 1 Month, So Why Does Wall Street Expect It to Rise 65%? (Motley Fool)
Jun-29-23 09:02AM	Biotech Stock Roundup: SRPT's DMD Therapy Approval, ICPT's Setback & More Updates (Zacks)
Jun-23-23 04:07PM	Sarepta Plummets Despite Winning FDA Nod For $3.2 Million Gene Therapy (Investor's Business Daily) -7.93%
Jun-22-23 05:17PM	The Price of First Gene Therapy for Muscular Dystrophy: $3.2 Million (The Wall Street Journal)
04:02PM	Sarepta Stock Yo-Yoes After Winning Highly Anticipated Gene Therapy Nod (Investor's Business Daily)
03:02PM	First gene therapy for deadly form of muscular dystrophy gets FDA approval for young kids (AP Finance)
02:24PM	Sarepta Wins FDA Approval For Highly Anticipated Gene Therapy (Investor's Business Daily)
02:23PM	First Gene Therapy for Muscular Dystrophy Approved (The Wall Street Journal)
02:08PM	UPDATE 4-US FDA approves Sarepta's gene therapy for rare muscular dystrophy in some kids (Reuters)
02:02PM	Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy (Business Wire)
Jun-17-23 09:45AM	Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Is Expected To Breakeven In The Near Future (Simply Wall St.)
Jun-12-23 09:30AM	3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon (InvestorPlace)
Jun-08-23 11:30AM	Mirati (MRTX) Down 17.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-01-23 11:31AM	Why Is Sarepta Therapeutics (SRPT) Down 1.5% Since Last Earnings Report? (Zacks)
10:04AM	15 Best Healthcare Stocks To Buy Now (Insider Monkey)
06:45AM	Is Sarepta Therapeutics' Gene Therapy in Danger of Not Obtaining FDA Approval? (Motley Fool)
May-31-23 06:16PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-24-23 04:04PM	Sarepta Therapeutics Dives On An Unexpected Holdup For Its Gene Therapy (Investor's Business Daily) -10.58%
01:53PM	Why Shares of Sarepta Therapeutics Are Dropping Wednesday (Motley Fool)
12:28PM	FDA Extends Review For Sarepta Therapeutics' Duchenne Gene Therapy By Couple Of Weeks (Benzinga)
09:53AM	2 Under-the-Radar Biotech Stocks to Buy in 2023 (Motley Fool)
08:24AM	UPDATE 2-FDA defers decision for Sarepta's gene therapy to June 22 from May 29 (Reuters)
08:07AM	FDA defers decision for Sarepta's gene therapy to June 22 (Reuters)
08:00AM	Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001 (Business Wire)
May-16-23 03:42PM	Why These 3 Nasdaq Stocks Buckled Today (Motley Fool) -5.12%
08:30AM	Gene-Therapy Investors Have a Powerful Ally: Patients (The Wall Street Journal)
May-15-23 04:05PM	Sarepta Stock Catapults Higher After Eking Out A Narrow Win In Its Gene Therapy Battle (Investor's Business Daily) +30.77%
12:48PM	Stocks to Watch Monday: Newmont, Oneok, Shake Shack (The Wall Street Journal)
10:59AM	Why Sarepta Therapeutics Stock Is Skyrocketing Today (Motley Fool)
10:30AM	Sarepta gains over $2B in market cap on new hope for Duchenne drug approval (American City Business Journals)
08:53AM	FDA AdComm Narrowly Supports Approval Of Sarepta's Gene Therapy For Rare Neuromuscular Disorder (Benzinga)
08:33AM	Sarepta surges after FDA panel backs Duchenne gene therapy (Reuters)
May-14-23 04:00PM	2 Supercharged Growth Stocks to Buy Right Now (Motley Fool)
May-12-23 07:02PM	Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy (Business Wire)
06:18PM	Sarepta Ekes Out A Narrow Win In Its Gene Therapy Battle; Shares Halted (Investor's Business Daily)
12:37PM	UPDATE 4-US FDA advisers narrowly back Sarepta's Duchenne gene therapy for accelerated approval (Reuters)
09:49AM	Sarepta Halted As FDA Mulls Its Highly Anticipated Gene Therapy (Investor's Business Daily)
May-11-23 02:23PM	Why Sarepta Therapeutics Stock Faded This Week (Motley Fool)
May-10-23 09:32AM	UPDATE 1-FDA reviewers flag concerns over Sarepta's gene therapy for muscle-wasting disorder (Reuters)
May-08-23 02:32AM	Weekly biotech pulse: Big catalysts on tap for Sarepta, Roche, Eyenovia, and more (Investing.com)
May-05-23 02:30PM	Institutional investors control 86% of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) and were rewarded last week after stock increased 6.6% (Simply Wall St.)
May-04-23 10:05AM	Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-03-23 11:36AM	Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y (Zacks)
07:27AM	Q1 2023 Sarepta Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
12:00AM	Sarepta Therapeutics (SRPT) Q1 2023 Earnings Call Transcript (Motley Fool)
May-02-23 05:35PM	Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments (Business Wire)
Apr-28-23 06:15PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-26-23 10:02AM	Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-25-23 08:30AM	Sarepta Therapeutics to Announce First Quarter 2023 Financial Results (Business Wire)
Apr-19-23 09:14AM	Risks To Shareholder Returns Are Elevated At These Prices For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) (Simply Wall St.)
Apr-13-23 04:05PM	Sarepta Tumbles As Report Of Internal FDA Strife Scorches Its Gene Therapy (Investor's Business Daily) -9.41%
11:03AM	Sarepta Therapeutics Stock Tumbles on Gene Therapy Drama (Barrons.com)
10:17AM	Midday movers: Delta Air Lines, Harley Davidson, Rent the Runway and more (Investing.com)
09:29AM	Sarepta shares drop as report says FDA almost rejected under-review gene therapy (Reuters)
Apr-10-23 09:37AM	Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023 (Business Wire)
Apr-06-23 05:39AM	2 Top Growth Stocks That Could Soar This Spring (Motley Fool)
Mar-31-23 06:25PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-30-23 11:30AM	Sarepta Therapeutics (SRPT) Down 6.2% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-29-23 09:26AM	Sarepta Therapeutics' (NASDAQ:SRPT) growing losses don't faze investors as the stock advances 3.7% this past week (Simply Wall St.)
Mar-25-23 06:00AM	3 Up-and-Coming Growth Stocks to Buy Right Now (Motley Fool)
Mar-21-23 04:16PM	Accelerated Approval For Gene Therapies - US Health Regulator Looks To Improve Process (Benzinga)
03:02AM	Sarepta Therapeutics (SRPT) Soars 7.1%: Is Further Upside Left in the Stock? (Zacks)
Mar-17-23 04:05PM	Sarepta Crashes On An Unexpected Roadblock For Its Gene Therapy (Investor's Business Daily) -18.03%
02:54PM	Sarepta (SRPT) Stock Down, FDA to Hold Panel Meet for SRP-9001 (Zacks)
02:00PM	Sarepta Plunges As FDA Takes Surprise Turn; AdComm Meeting Set For Duchenne Gene Therapy (Benzinga)
01:20PM	Why Weakness in Sarepta Therapeutics Is Likely to Continue (TheStreet.com)
11:39AM	First Republic Banks stock plunge continues despite $30 billion bank boost, FedExs stock jumps after blowout earnings report (MarketWatch)
11:22AM	Sarepta Therapeutics Plunges on Drug Approval Doubts. Buy the Stock, Analysts Say. (Barrons.com)
09:50AM	The 2 Stocks to Watch on a Nail-Biter Friday (Motley Fool)

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chambers Michael Andrew	Director	Aug 14	Buy	109.47	9,979	1,092,429	246,996	Aug 15 08:00 AM
Chambers Michael Andrew	Director	Aug 11	Buy	108.05	23,686	2,559,272	237,017	Aug 14 08:00 AM
Chambers Michael Andrew	Director	Aug 10	Buy	106.15	34,867	3,701,067	213,331	Aug 11 07:40 AM
Wigzell Hans Lennart Rudolf	Director	Aug 04	Option Exercise	29.03	15,000	435,450	35,994	Aug 08 08:00 PM
Wigzell Hans Lennart Rudolf	Director	Aug 04	Sale	106.72	15,000	1,600,800	20,994	Aug 08 08:00 PM
BEHRENS M KATHLEEN	Director	Dec 19	Option Exercise	34.92	20,000	698,400	158,470	Dec 21 09:05 AM
Mayo Stephen	Director	Nov 17	Sale	109.92	858	94,311	6,387	Nov 21 08:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SRPT | Sarepta Therapeutics Inc

Upgrade your FINVIZ experience